Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Meagher

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse OutcomesNicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Nature Communications|April 1, 2026
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Cancer|December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyEun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse OutcomesNicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Nature Communications|April 1, 2026
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Cancer|December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyEun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Sian Fereday, Ahwan Pandey, et al.
Pageof 9